Neuregen Biotech announced the completion of Series A financing. This Series A financing was led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund Partnership (Limited ...

In view of the biological complexity and treatment limitations of high-grade brain gliomas, NRG-103 injection is designed through the triple mechanism of quotin situ cell transdifferentiation + oncoly...

NRG-103 injection is an innovative product for the treatment of glioblastoma based on Nerenger's independently developed in situ transdifferentiation technology, also known as in vivo cell reprogrammi...

On August 11, 2025, Neuregen Bio., hereinafter referred to as Neuregen , announced that its independently developed world's first innovative drug NRG-103 injection based on in situ transformation tech...

Recently, the first National Disruptive Technology Entrepreneurship Star List was officially released in Guangzhou. Neuregen Biotech was successfully selected as the first National Disruptive Technolo...

NRG-103 is a new therapy for malignant glioma developed by Neuregen Biotech based on its independent intellectual property rights in situ transformation technology platform. On the basis of immune kil...

After three months of fierce competition, Neuregen Biotech stood out from thousands of companies and won the first place in the Life and Health Track with its in-situ transformation technology! This ...

On December 16, 2024, the kick-off meeting of the clinical research project on the safety and effectiveness of NRG-103 injection in the treatment of patients with recurrent glioblastoma jointly carrie...